Cambridge Investment Research Advisors Inc. grew its stake in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) by 41.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,070 shares of the company’s stock after acquiring an additional 2,370 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in BioXcel Therapeutics were worth $348,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of BTAI. Lindbrook Capital LLC lifted its position in BioXcel Therapeutics by 314.1% during the first quarter. Lindbrook Capital LLC now owns 762 shares of the company’s stock worth $33,000 after buying an additional 578 shares during the period. Citigroup Inc. raised its holdings in shares of BioXcel Therapeutics by 92.4% in the 4th quarter. Citigroup Inc. now owns 2,877 shares of the company’s stock worth $133,000 after purchasing an additional 1,382 shares during the period. Twinbeech Capital LP purchased a new position in shares of BioXcel Therapeutics in the 4th quarter worth about $208,000. Principal Financial Group Inc. purchased a new position in shares of BioXcel Therapeutics in the 4th quarter worth about $213,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of BioXcel Therapeutics by 176.9% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,083 shares of the company’s stock worth $219,000 after purchasing an additional 3,247 shares during the period. Institutional investors and hedge funds own 44.61% of the company’s stock.
Shares of NASDAQ BTAI opened at $37.32 on Wednesday. The company has a market cap of $919.27 million, a P/E ratio of -9.15 and a beta of 1.10. BioXcel Therapeutics, Inc. has a 12-month low of $28.00 and a 12-month high of $71.50. The business has a 50 day moving average of $33.93.
BioXcel Therapeutics (NASDAQ:BTAI) last announced its quarterly earnings results on Sunday, May 9th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.19). Equities research analysts expect that BioXcel Therapeutics, Inc. will post -4.48 earnings per share for the current year.
A number of equities research analysts have recently issued reports on BTAI shares. Berenberg Bank started coverage on BioXcel Therapeutics in a research note on Friday, April 9th. They issued a “buy” rating and a $75.00 target price for the company. Truist Securities lowered their price objective on BioXcel Therapeutics from $150.00 to $127.00 and set a “buy” rating for the company in a research note on Thursday, April 1st. HC Wainwright raised their price objective on BioXcel Therapeutics from $170.00 to $176.00 and gave the company a “buy” rating in a research note on Tuesday, June 1st. Truist lowered their price objective on BioXcel Therapeutics from $150.00 to $127.00 in a research note on Thursday, April 1st. Finally, Canaccord Genuity lowered their price objective on BioXcel Therapeutics from $110.00 to $95.00 and set a “buy” rating for the company in a research note on Thursday, April 1st. Eleven research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $101.91.
BioXcel Therapeutics Profile
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors.
Featured Story: 52- Week Highs
Want to see what other hedge funds are holding BTAI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioXcel Therapeutics, Inc. (NASDAQ:BTAI).